Concurrently, SGLT1 inhibition mitigates side effects associated with SGLT2 inhibitors, including a lower incidence of DKA, urinary tract infections, and improved acid-base buffering capacity (7, 8). The gene discussed is SLC5A2; the disease is urinary tract infection.